Bristol-Myers Squibb  $^{ }$Note 5 OTHER (INCOME)/EXPENSE  $^{ }$Note 6 RESTRUCTURING  The final purchase price allocation for ZymoGenetics, Amira and Inhibitex and the preliminary purchase price allocation (pending  final valuation of intangible assets and deferred income taxes) for Amylin were as follows:  Cash paid for the acquisition of Amylin included payments of $5,093 million to its outstanding common stockholders and $219  million to holders of its stock options and restricted stock units (including $94 million attributed to accelerated vesting that was  accounted for as stock compensation expense in the third quarter of 2012).  The results of operations from acquired companies are included in the consolidated financial statements as of the acquisition date.  Revisions to goodwill from preliminary estimates at September 30, 2012 for Amylin relate primarily to an adjustment of the  preliminary amount allocated to the fair value of acquired IPRD (decrease of $250 million) based on additional information obtained  related to future cash flow projections, net of the resulting deferred tax adjustment ($99 million).  Pro forma supplemental financial information is not provided as the impacts of the acquisitions were not material to operating results  in the year of acquisition. Goodwill, IPRD and all intangible assets valued in these acquisitions are non-deductible for tax purposes . $^{ }$The following is the provision for restructuring:  44 Year Ended December 31,  Dollars in Millions 2012 2011 2010 Employee termination benefits $  145  $  85 $  102  Other exit costs   29   31  11  Provision for restructuring  $  174  $   116 $  113  Year Ended December 31,  Dollars in Millions 2012 2011 2010 Interest expense $  182 $   145 $  145 Investment income   (106)   (91)   (75)  Provision for restructuring (See Note 6)   174  116  113 Litigation charges/(recoveries)   (45)   6  (2)  Equity in net income of affiliates   (183)   (281)   (313)  Impairment and loss on sale of manufacturing operations   -  -  236 Out-licensed intangible asset impairment   38  - Gain on sale of product lines, businesses and assets   (53)   (37)   (39)  Other income received from alliance partners, net   (312)  (140)  (137) Pension curtailments and settlements   158   10   28  Other   67  (62)   (49)  Other (income)/expense  $  (80)  $   (334)  $  (93)  Other (income)/expense includes:  Dollars in Millions Amylin Inhibitex Amira  ZymoGenetics Identifiable net assets:  Cash $  179 $  46 $   15 $  56  Marketable securities   108  17  -  91  Inventory   173  -  98  Property, plant and equipment   742  -  -  Developed technology rights   6,340  -  230  IPRD   120  1,875  160  448  Other assets   136  -  -  29  Debt obligations   (2,020)  (23)  -  Other liabilities   (339) (10) (16) (91) Deferred income taxes   (1,057) (579) (41) 9  Total identifiable net assets   4,382  1,326  118  870  Goodwill   836  1,213  265  15  Purchase price to be allocated  $  5,218 $  2,539 $   383 $  885 